AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8241702 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg per day) given orally for 14 days before and 30 days after surgery
Number of subjects: 10
Study 8241702 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 10
Study 8241702 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg per day)
Number of subjects: 10
Study 2859412 — intervention group
Group type: EXPERIMENTAL
Intervention: HB immunoglobulin and 2 doses of HB vaccine 2 months apart
Number of subjects: 214
Study 2859412 — intervention group
Group type: COMPARATOR
Intervention: HB immunoglobulin and 3 doses of HB vaccine 1 month apart
Number of subjects: 214
Study 2859412 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of vaccine 2 months apart
Number of subjects: 214
Study 2859412 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of vaccine 1 month apart
Number of subjects: 214
Study 2859412 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose regimen
Number of subjects: 214
Study 2859412 — intervention group
Group type: COMPARATOR
Intervention: 3-dose regimen
Number of subjects: 214
Study 30982467 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Cogmed training
Number of subjects: 100
Study 30982467 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive Cogmed training (control)
Number of subjects: 100
Study 29400641 — intervention group
Group type: COMPARATOR
Intervention: Normal
Number of subjects: 0
Study 29400641 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 0
Study 29400641 — intervention group
Group type: EXPERIMENTAL
Intervention: Wernicke‐Korsakoff Syndrome (WKS)
Number of subjects: 0
Study 29400641 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic traumatic encephalopathy (CTE)
Number of subjects: 0
Study 26524984 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB‐UVB) exposures, 2 standard erythema doses (SEDs) every second week from October 2013 to April 2014
Number of subjects: 34
Study 26524984 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NB‐UVB exposure)
Number of subjects: 34
Study 24485082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 60
Study 24485082 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 60
Study 22878869 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron (0.1 mg/kg; maximal dose, 5 mg)
Number of subjects: 120
Study 22878869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (0.1 mg/kg; maximal dose, 5 mg) plus Penehyclidine (0.01 mg/kg; maximal dose, 1 mg)
Number of subjects: 120
Study 22878869 — intervention group
Group type: COMPARATOR
Intervention: Penehyclidine (0.01 mg/kg; maximal dose, 1 mg)
Number of subjects: 120
Study 22878869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron plus Penehyclidine
Number of subjects: 120
Study 22878869 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron
Number of subjects: 120
Study 22878869 — intervention group
Group type: COMPARATOR
Intervention: Penehyclidine
Number of subjects: 120
Study 20876698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with high effect-site concentration of remifentanil (SH)
Number of subjects: 214
Study 20876698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with low effect-site concentration of remifentanil (SL)
Number of subjects: 214
Study 20876698 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with high effect-site concentration of remifentanil (PH)
Number of subjects: 214
Study 20876698 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with low effect-site concentration of remifentanil (PL)
Number of subjects: 214
Study 18947293 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE One (new premixed self-etching adhesive)
Number of subjects: 40
Study 18947293 — intervention group
Group type: COMPARATOR
Intervention: Transbond Plus (self-etching primer)
Number of subjects: 40
Study 15867284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet with 25 g/d soy protein (+ 90 mg/d isoflavones)
Number of subjects: 32
Study 15867284 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-fiber diet with 25 g/d milk protein
Number of subjects: 32
Study 15867284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CRP group (regardless of protein source)
Number of subjects: 32
Study 15867284 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP group (regardless of protein source)
Number of subjects: 32
Study 12975413 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta MHC gene mutation
Number of subjects: 70
Study 12975413 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 70
Study 11593526 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 to 50 mg bid for 12 weeks
Number of subjects: 278
Study 9038448 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive technique using a neonatal oscillometric blood pressure monitor attached to the thumb
Number of subjects: 18
Study 9038448 — intervention group
Group type: COMPARATOR
Intervention: Invasive technique using a catheter inserted into the ipsilateral radial artery
Number of subjects: 18
Study 1531286 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg)
Number of subjects: 95
Study 1531286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms/kg)
Number of subjects: 95
Study 1531286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 95
Study 1531286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 95
Study 3934964 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic therapy
Number of subjects: 57
Study 3934964 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg per day of sorbinil
Number of subjects: 57
Study 3934964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31142290 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training including aerobic and resistance exercises of moderate/high intensity
Number of subjects: 540
Study 31142290 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 540
Study 28843487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg orally twice daily
Number of subjects: 25
Study 28843487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 25
Study 25911523 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote therapy from University lab
Number of subjects: 21
Study 25911523 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote therapy from clinical site
Number of subjects: 21
Study 25911523 — intervention group
Group type: EXPERIMENTAL
Intervention: Face to face therapy
Number of subjects: 21
Study 25911523 — intervention group
Group type: COMPARATOR
Intervention: Attention control (remotely delivered supported conversation)
Number of subjects: 21
Study 24407777 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-triggered regimen of lorazepam
Number of subjects: 63
Study 24407777 — intervention group
Group type: COMPARATOR
Intervention: Fixed tapering dose regimen of lorazepam
Number of subjects: 63
Study 24407777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 20478467 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl for 10 minutes
Number of subjects: 20
Study 20478467 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% H2O2 for 10 minutes
Number of subjects: 20
Study 20478467 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA for 10 minutes
Number of subjects: 20
Study 20478467 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 20
Study 15944868 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen patch for 36 hours
Number of subjects: 19
Study 15944868 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch for 36 hours
Number of subjects: 19
Study 12218734 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training (PT) for 4 months
Number of subjects: 0
Study 12218734 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 0
Study 9498887 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg midazolam
Number of subjects: 80
Study 9498887 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam
Number of subjects: 80
Study 9498887 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.25 mg midazolam
Number of subjects: 80
Study 9498887 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 80
Study 9498887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8147070 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (D) - 300 micrograms/kg bolus and 5.4 micrograms/kg/min continuous infusion
Number of subjects: 20
Study 8147070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (N) - 5 micrograms/kg bolus and 0.2 micrograms/kg/min continuous infusion
Number of subjects: 20
Study 8147070 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study 3168559 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral intestinal cleansing with 1.5 l cold electrolyte solution
Number of subjects: 55
Study 3168559 — intervention group
Group type: COMPARATOR
Intervention: Rectal lavaging
Number of subjects: 55
Study 11903525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous valproate 500 mg
Number of subjects: 40
Study 11903525 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular dihydroergotamine 1 mg with metoclopramide 10 mg
Number of subjects: 40
Study 11903525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous valproate
Number of subjects: 40
Study 11903525 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular dihydroergotamine
Number of subjects: 40
Study 30488954 — intervention group
Group type: EXPERIMENTAL
Intervention: Video modelling intervention (brief video model created by a dentist)
Number of subjects: 40
Study 30488954 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 40
Study 29443825 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV)
Number of subjects: 10002
Study 29443825 — intervention group
Group type: COMPARATOR
Intervention: Control (saline placebo or quadrivalent meningococcal conjugate vaccine)
Number of subjects: 10002
Study 27267860 — intervention group
Group type: EXPERIMENTAL
Intervention: Right LLLT (transcranial laser stimulation)
Number of subjects: 51
Study 27267860 — intervention group
Group type: COMPARATOR
Intervention: Left LLLT (transcranial laser stimulation)
Number of subjects: 51
Study 27267860 — intervention group
Group type: COMPARATOR
Intervention: Sham LLLT (control group)
Number of subjects: 51
Study 25064429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy set-back of the mandible (BSSO)
Number of subjects: 83
Study 25064429 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort I advancement of the maxilla
Number of subjects: 83
Study 25064429 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both BSSO and Le Fort I
Number of subjects: 83
Study 22801294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole extended-release (ER) once daily for 12 weeks, titrated to a maximum daily dose of 4.5 mg
Number of subjects: 112
Study 22801294 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole immediate-release (IR) 2 to 3 times daily for 12 weeks, titrated to a maximum daily dose of 4.5 mg
Number of subjects: 112
Study 22801294 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label pramipexole ER after switching from IR
Number of subjects: 112
Study 22801294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ER and IR formulations
Number of subjects: 112
Study 20530645 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (affected arm trained for 3 hours/day, non-affected arm restricted for 10 hours/day for two weeks)
Number of subjects: 16
Study 20530645 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual rehabilitation)
Number of subjects: 16
Study 17626023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (GPs receiving the educational intervention)
Number of subjects: 104
Study 17626023 — intervention group
Group type: COMPARATOR
Intervention: Control group (GPs not receiving the educational intervention)
Number of subjects: 104
Study 14693782 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 59
Study 14693782 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 59
Study 12224977 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream applied once daily for 7 days per week for 6 weeks
Number of subjects: 191
Study 12224977 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream applied once daily for 7 days per week for 12 weeks
Number of subjects: 191
Study 12224977 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (placebo) applied once daily for 3, 5, or 7 days per week, or twice daily for 7 days per week for 12 weeks
Number of subjects: 191
Study 9853487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 139
Study 9853487 — intervention group
Group type: COMPARATOR
Intervention: Cementless fixation
Number of subjects: 139
Study 7978560 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol treatments (1990)
Number of subjects: 176
Study 7978560 — intervention group
Group type: COMPARATOR
Intervention: Control group (1988)
Number of subjects: 176
Study 2687818 — intervention group
Group type: EXPERIMENTAL
Intervention: Immucytal
Number of subjects: 120
Study 2687818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 4577015 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural corticosteroid injection
Number of subjects: 100
Study 4577015 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 31722314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride extended-release tablets
Number of subjects: 20
Study 31722314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28671495 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified classical music
Number of subjects: 74
Study 28671495 — intervention group
Group type: EXPERIMENTAL
Intervention: Original classical music
Number of subjects: 74
Study 28671495 — intervention group
Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 74
Study 25966608 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 119
Study 25966608 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 119
Study 22777149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day
Number of subjects: 33
Study 22777149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 33
Study 22777149 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 33
Study 21751288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1 mmol/kg)
Number of subjects: 10
Study 21751288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid (0.05 mmol/kg)
Number of subjects: 10
Study 21751288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid
Number of subjects: 10
Study 21751288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 10
Study 18160390 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-hour pre-study training course on knowledge about lactation and guidance for breastfeeding
Number of subjects: 109
Study 18160390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers receiving support from health visitors who completed the training course
Number of subjects: 109
Study 16585298 — intervention group
Group type: EXPERIMENTAL
Intervention: The Asthma Files, an interactive CD‐ROM for children with asthma
Number of subjects: 101
Study 16585298 — intervention group
Group type: COMPARATOR
Intervention: Asthma information booklet alone
Number of subjects: 101
Study 15296365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatherm
Number of subjects: 30
Study 15296365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist heat pack
Number of subjects: 30
Study 15296365 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 11128567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg)
Number of subjects: 149
Study 11128567 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (1.5 mg/kg, i.v.)
Number of subjects: 149
Study 9060534 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy boost to the tumor bed
Number of subjects: 1024
Study 9060534 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 1024
Study 8328095 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous pushing (closed glottis technique)
Number of subjects: 350
Study 8328095 — intervention group
Group type: EXPERIMENTAL
Intervention: Open glottis technique
Number of subjects: 350
Study 8328095 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous bearing down efforts
Number of subjects: 350
Study 8328095 — intervention group
Group type: COMPARATOR
Intervention: Forced pushing (closed glottis technique)
Number of subjects: 350
Study 2873741 — intervention group
Group type: EXPERIMENTAL
Intervention: Special-intervention (SI) program aimed at reducing serum cholesterol levels, blood pressure, and cigarette smoking
Number of subjects: 12866
Study 2873741 — intervention group
Group type: EXPERIMENTAL
Intervention: Special-intervention (SI) program
Number of subjects: 12866
Study 2873741 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 12866
Study 30646083 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving education (PSE)
Number of subjects: 230
Study 30646083 — intervention group
Group type: COMPARATOR
Intervention: Usual Head Start services (control)
Number of subjects: 230
Study 26303665 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation in the bed nucleus of the stria terminalis (BST)
Number of subjects: 24
Study 26303665 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation in the anterior limbs of the internal capsule (ALIC)
Number of subjects: 24
Study 25536218 — intervention group
Group type: EXPERIMENTAL
Intervention: Incobotulinumtoxin A
Number of subjects: 10
Study 22763815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and prednisolone
Number of subjects: 131
Study 22763815 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and prednisolone
Number of subjects: 131
Study 22763815 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 131
Study 22763815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 131
Study 20028444 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (50 microg/mL) ophthalmic solution applied nightly to eyelid margins
Number of subjects: 54
Study 20028444 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving triamcinolone acetonide (TAC) injections
Number of subjects: 54
Study 17894912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (intraoperative bolus of 0.15 mg kg‐1, followed by 0.5 mg per morphine 1 mg in a patient‐controlled analgesia device)
Number of subjects: 90
Study 17894912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (as above)
Number of subjects: 90
Study 17894912 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 90
Study 15837984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) using radioactive colloid, lymphazurin blue dye, or both
Number of subjects: 428
Study 15837984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) using radioisotope
Number of subjects: 428
Study 15837984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 428
Study 12190090 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy with omeprazole for 3 months
Number of subjects: 143
Study 12190090 — intervention group
Group type: COMPARATOR
Intervention: Placebo antibiotics with omeprazole for 3 months
Number of subjects: 143
Study 12190090 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy in patients with antrum-predominant gastritis
Number of subjects: 143
Study 12190090 — intervention group
Group type: COMPARATOR
Intervention: Ongoing infection in controls with antrum-predominant gastritis
Number of subjects: 143
Study 12190090 — intervention group
Group type: EXPERIMENTAL
Intervention: High urease activity of the stomach
Number of subjects: 143
Study 10520210 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives of early onset lung cancer cases
Number of subjects: 384
Study 10520210 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of cases with adenocarcinoma of the lung
Number of subjects: 384
Study 10520210 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of cases
Number of subjects: 384
Study 10520210 — intervention group
Group type: EXPERIMENTAL
Intervention: Case families
Number of subjects: 384
Study 8625221 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 150 micrograms subcutaneously three times daily
Number of subjects: 260
Study 8625221 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injections
Number of subjects: 260
Study 2205768 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior notification process used in firm trials
Number of subjects: 0
Study 7384318 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up care (3 forms)
Number of subjects: 129
Study 7384318 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive patients
Number of subjects: 129
Study 7384318 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rating as 'slow, dependent, and weak'
Number of subjects: 129
Study 30981962 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid ankle brace (T1)
Number of subjects: 42
Study 30981962 — intervention group
Group type: EXPERIMENTAL
Intervention: Softshell ankle brace (AE)
Number of subjects: 42